Cargando…

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience

BACKGROUND: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Nevertheless, there is sparsely data concerning the management of elderly patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Schelker, Roland Christian, Herr, Wolfgang, Reichle, Albrecht, Vogelhuber, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195694/
https://www.ncbi.nlm.nih.gov/pubmed/30340554
http://dx.doi.org/10.1186/s12885-018-4885-5
_version_ 1783364435985825792
author Schelker, Roland Christian
Herr, Wolfgang
Reichle, Albrecht
Vogelhuber, Martin
author_facet Schelker, Roland Christian
Herr, Wolfgang
Reichle, Albrecht
Vogelhuber, Martin
author_sort Schelker, Roland Christian
collection PubMed
description BACKGROUND: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Nevertheless, there is sparsely data concerning the management of elderly patients. METHODS: We performed a retrospective study of treatment with rituximab and low-dose trofosfamide in elderly patients (≥ 75 years) with DLBCL who were not suitable for R-CHOP or R-CHOP-like regimens or who did not consent to aggressive treatment. The choice regarding the qualification for R-CHOP or R-CHOP-like regimen was left to the estimation of the treating physicians. RESULTS: Eleven patients with a median age of 83 years (range, 75–90 years) were included. The age-adjusted international prognostic index was low risk in one patient, low-intermediate in four patients, high-intermediate in three patients, and high risk in 3 patients. All patients were evaluable for response. Five patients (45%) achieved a complete response, three (27%) a partial response, one (9%) stable disease, and two (18%) progressive disease. The estimated 1-yr overall survival was 54.5%, and the estimated 1-yr progression-free survival 45.5%, however, three patients (27%) were alive without evidence of disease at 16–20 months from start of treatment. Main toxicity was leukopenia (36% grade III or IV), whereas grade III/IV non-hematological adverse events did not occur. CONCLUSIONS: Due to its potency and low toxicity, trofosfamide/rituximab might represent an alternative therapy for DLBCL of elderly patients not suitable for R-CHOP. This observation, however, should be confirmed in a larger patient population within a prospective clinical trial.
format Online
Article
Text
id pubmed-6195694
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61956942018-10-30 Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience Schelker, Roland Christian Herr, Wolfgang Reichle, Albrecht Vogelhuber, Martin BMC Cancer Research Article BACKGROUND: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Nevertheless, there is sparsely data concerning the management of elderly patients. METHODS: We performed a retrospective study of treatment with rituximab and low-dose trofosfamide in elderly patients (≥ 75 years) with DLBCL who were not suitable for R-CHOP or R-CHOP-like regimens or who did not consent to aggressive treatment. The choice regarding the qualification for R-CHOP or R-CHOP-like regimen was left to the estimation of the treating physicians. RESULTS: Eleven patients with a median age of 83 years (range, 75–90 years) were included. The age-adjusted international prognostic index was low risk in one patient, low-intermediate in four patients, high-intermediate in three patients, and high risk in 3 patients. All patients were evaluable for response. Five patients (45%) achieved a complete response, three (27%) a partial response, one (9%) stable disease, and two (18%) progressive disease. The estimated 1-yr overall survival was 54.5%, and the estimated 1-yr progression-free survival 45.5%, however, three patients (27%) were alive without evidence of disease at 16–20 months from start of treatment. Main toxicity was leukopenia (36% grade III or IV), whereas grade III/IV non-hematological adverse events did not occur. CONCLUSIONS: Due to its potency and low toxicity, trofosfamide/rituximab might represent an alternative therapy for DLBCL of elderly patients not suitable for R-CHOP. This observation, however, should be confirmed in a larger patient population within a prospective clinical trial. BioMed Central 2018-10-19 /pmc/articles/PMC6195694/ /pubmed/30340554 http://dx.doi.org/10.1186/s12885-018-4885-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Schelker, Roland Christian
Herr, Wolfgang
Reichle, Albrecht
Vogelhuber, Martin
Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
title Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
title_full Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
title_fullStr Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
title_full_unstemmed Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
title_short Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
title_sort low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large b-cell lymphoma of the elderly: a single center experience
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195694/
https://www.ncbi.nlm.nih.gov/pubmed/30340554
http://dx.doi.org/10.1186/s12885-018-4885-5
work_keys_str_mv AT schelkerrolandchristian lowdosetrofosfamideplusrituximabisaneffectiveandsafetreatmentfordiffuselargebcelllymphomaoftheelderlyasinglecenterexperience
AT herrwolfgang lowdosetrofosfamideplusrituximabisaneffectiveandsafetreatmentfordiffuselargebcelllymphomaoftheelderlyasinglecenterexperience
AT reichlealbrecht lowdosetrofosfamideplusrituximabisaneffectiveandsafetreatmentfordiffuselargebcelllymphomaoftheelderlyasinglecenterexperience
AT vogelhubermartin lowdosetrofosfamideplusrituximabisaneffectiveandsafetreatmentfordiffuselargebcelllymphomaoftheelderlyasinglecenterexperience